UXG-300 is a bile acid–based medication widely used for the management of various liver and gallbladder disorders. UDCA is a naturally occurring hydrophilic bile acid that helps improve bile flow, protect liver cells, and reduce the formation of toxic bile acids. It is particularly beneficial in conditions characterized by impaired bile secretion or obstruction, making it a preferred treatment in many chronic cholestatic disorders. This medication works through multiple mechanisms. It decreases the cholesterol content in bile by reducing its absorption and secretion in the liver, which helps dissolve small to medium-sized cholesterol gallstones in patients who cannot undergo surgery. UDCA also enhances the flow of bile through the liver and biliary tract, reducing cholestasis and alleviating symptoms such as jaundice, itching, and fatigue. Additionally, it stabilizes liver cell membranes, protecting them from injury caused by toxic bile acids, inflammation, or oxidative stress. UXG-300 is most commonly prescribed for primary biliary cholangitis (PBC), gallstone dissolution in patients with functioning gallbladders, and certain types of cholestatic liver disease including drug-induced liver injury, cystic fibrosis–related hepatobiliary disease, and pregnancy-related cholestasis under medical supervision. It may also be used as supportive therapy in fatty liver disease when bile flow abnormalities are present. The tablet is usually taken with food to enhance absorption. Treatment duration can vary from several months to long-term use, depending on the condition. UDCA is generally well tolerated, with mild side effects such as diarrhea, nausea, or abdominal discomfort in some individuals. It should be used cautiously in patients with complete biliary obstruction or severe liver failure. Regular monitoring of liver function tests is often recommended during therapy. Overall, UXG-300 remains an effective and reliable therapy to improve bile circulation, support liver health, and manage gallstone-related conditions, helping patients maintain better hepatic function and overall well-being.
| Packing | 10*1*10 (A/A) |
| GST | 5% |